MedTrace Logo

Study to Gain Insights in Treatment Patterns and Outcomes in Patients With Atherosclerosis Prescribed to Xarelto in Combination With Acetylsalicylic Acid

NCT03746275 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5798

Last updated 2022-05-02

No results posted yet for this study

Summary

In this study researchers want to gain more information on treatment patterns of patients treated with Xarelto in combination with acetylsalicylic acid (ASA). Both drugs reduce the risk of blood clots via different pathways. The study will enroll adult patients suffering from coronary artery disease (narrowing or blockage of vessels that supply the heart with blood) or peripheral artery disease (narrowing or blockage of vessels that supply the legs or head with blood). The study will focus on information on when and why physicians are starting to treat patients with Xarelto in addition to ASA, treatment duration, reasons to discontinue treatment and previous therapies. The study will also look into treatment outcomes for patients being treated with a combination of Xarelto and ASA by their physicians.

Conditions

Interventions

DRUG

Rivaroxaban (BAY59-7939, Xarelto)

2.5 mg twice daily

DRUG

Acetylsalicylic acid

75 - 100 mg once daily according to local label

Sponsors & Collaborators

  • Janssen, LP

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-13
Primary Completion
2021-06-08
Completion
2021-07-13

Countries

  • Argentina
  • Brazil
  • Canada
  • Denmark
  • Germany
  • Israel
  • Lebanon
  • Luxembourg
  • Mexico
  • Norway
  • Russia
  • Slovenia
  • South Korea
  • Sweden
  • Switzerland
  • Thailand
  • United Arab Emirates
  • United Kingdom

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746275 on ClinicalTrials.gov